[
  {
    "ts": null,
    "headline": "U.S. DTC Wellness Testing Market Forecast to 2030: A $1.91 Billion Opportunity Featuring Strategic Analysis of 23andMe, Everlywell, Quest Diagnostics and Other Industry Leaders",
    "summary": "The market presents opportunities driven by rising consumer awareness of preventive health, demand for personalized care, and digital healthcare integration U.S. DTC Wellness Testing Market U.S. DTC Wellness Testing Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"United States DTC Wellness Testing Market, By Region, Competition, Forecast & Opportunities, 2020-2030F\" has been added to ResearchAndMarkets.com's offering. The United States DTC Wellness Testing Market was valued at USD 1.05 Bil",
    "url": "https://finnhub.io/api/news?id=018220a4aa28381aa0ffd51165fa62ca6ab69dc3b5eca0205efd950aae89eae7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753284360,
      "headline": "U.S. DTC Wellness Testing Market Forecast to 2030: A $1.91 Billion Opportunity Featuring Strategic Analysis of 23andMe, Everlywell, Quest Diagnostics and Other Industry Leaders",
      "id": 136053333,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "The market presents opportunities driven by rising consumer awareness of preventive health, demand for personalized care, and digital healthcare integration U.S. DTC Wellness Testing Market U.S. DTC Wellness Testing Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"United States DTC Wellness Testing Market, By Region, Competition, Forecast & Opportunities, 2020-2030F\" has been added to ResearchAndMarkets.com's offering. The United States DTC Wellness Testing Market was valued at USD 1.05 Bil",
      "url": "https://finnhub.io/api/news?id=018220a4aa28381aa0ffd51165fa62ca6ab69dc3b5eca0205efd950aae89eae7"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Inc (DGX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ...",
    "summary": "Quest Diagnostics Inc (DGX) reports a 15.2% revenue increase and raises full-year guidance amid robust performance and strategic expansions.",
    "url": "https://finnhub.io/api/news?id=9df6a018b1b85b0a006e93e9f9a486862b56cba2c469fd9ee30f44439e80df90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753254365,
      "headline": "Quest Diagnostics Inc (DGX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ...",
      "id": 136039778,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics Inc (DGX) reports a 15.2% revenue increase and raises full-year guidance amid robust performance and strategic expansions.",
      "url": "https://finnhub.io/api/news?id=9df6a018b1b85b0a006e93e9f9a486862b56cba2c469fd9ee30f44439e80df90"
    }
  },
  {
    "ts": null,
    "headline": "DGX Q2 Deep Dive: Acquisitions, Advanced Diagnostics, and Utilization Trends Drive Growth",
    "summary": "Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.2% year on year to $2.76 billion. The company’s full-year revenue guidance of $10.86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $2.64 per share was 2.5% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=1e5bc2be925793b2837f42e6dfc6d6330ec3d73f956d1b9f9830dd7b296ddb2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753248969,
      "headline": "DGX Q2 Deep Dive: Acquisitions, Advanced Diagnostics, and Utilization Trends Drive Growth",
      "id": 136044578,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.2% year on year to $2.76 billion. The company’s full-year revenue guidance of $10.86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $2.64 per share was 2.5% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=1e5bc2be925793b2837f42e6dfc6d6330ec3d73f956d1b9f9830dd7b296ddb2f"
    }
  }
]